Study study type PathologyT1T0Patientssample sizesROB Results

laNSCLC - M - all population locally advanced NSCLC - maintenance (M) laNSCLC - M - all population

versus placebo
durvalumab alone
PACIFIC, 2017
  NCT02125461
RCTlaNSCLC - M - all populationDurvalumab as consolidation therapyplacebopatients with stage III unresectable NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy (consolidation therapy)476 / 237low
conclusif
  • demonstrated 32 % decrease in deaths (OS) (PE)
  • demonstrated 48 % decrease in progression or deaths (PFS) (PE)
  • suggested 28 % decrease in deaths (OS) (extension)
  • suggested 45 % decrease in PFS (extension)
  • more...

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)
durvalumab alone
MYSTIC (D ; all population), 2020
  NCT02453282
RCTmNSCLC - L1 - all populationdurvalumabplatinum-based doublet chemotherapyfirst-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%374 / 372some concern
inconclusive
    no statistically significant result

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
durvalumab alone
MYSTIC (D ; PDL1>25%), 2020
  NCT02453282
RCTmNSCLC - L1 - PDL1 positivedurvalumabplatinum-based doublet chemotherapyfirst-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%163 / 162some concern
inconclusive
  • inconclusive 24 % decrease in deaths (OS) (PE)

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus Standard of Care (SoC)
durvalumab alone
ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020
  NCT02352948
RCTmNSCLC - L2 - PDL1 positivedurvalumabstandard of care : erlotinib, gemcitabine or vinorelbinepatients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;62 / 64some concern
suggested
  • suggested 37 % decrease in deaths (OS)